Forma Therapeutics - About the company
Forma Therapeutics is an acquired company based in Watertown (United States), founded in 2007 by and . It operates as a Developer of therapeutic solutions for multiple health purposes. Forma Therapeutics has raised $418M in funding from investors like Celgene, RA Capital Management and Lilly Ventures. The company has 3336 active competitors, including 1163 funded and 774 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and BeiGene.
Company Details
Developer of therapeutic solutions for multiple health purposes. The company's lead products include FT-4202 PKR activator for sickle cell diseases, FT-7051 for acute myeloid leukemia, OLUTASIDENIB for glioma, and many more. The company’s drug discovery engine deploys screening and structure-based approaches across various families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions.
- Website
- Social
- Email ID
- @formatherapeutics.com
- Phone Number
- +1
Key Metrics
Founded Year
2007
Location
Watertown, United States
Stage
Acquired
Total Funding
in 8 rounds
Latest Funding Round
Investors
Ranked
218th among 3336 active competitors
Employee Count
as on Dec 31, 2021
Similar Companies
Exit Details
Acquired by Novo Nordisk (Sep 01, 2022)
Legal entities associated with Forma Therapeutics
Forma Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Dec 14, 2011 | - | 363 | 547 | |
Dec 31, 1999 | - | 524 | 413 |
Get your free copy of Forma Therapeutics's company profile
Forma Therapeutics's acquisition details
Forma Therapeutics got acquired by Novo Nordisk on Sep 01, 2022 at an acquisition amount of $1.1B. It was facilitated by Davis Polk and Moelis & Company.
Click to take a look at Forma Therapeutics's acquisition in detail
Forma Therapeutics's funding and investors
Forma Therapeutics has raised a total funding of $418M over 8 rounds. Its first funding round was on Mar 18, 2008. Its latest funding round was a Series D round on Dec 19, 2019 for $100M. 4 investors participated in its latest round, which includes Novartis Venture Fund, Wellington, HTIF and EDBI.
Forma Therapeutics has 15 institutional investors including Celgene, RA Capital Management and Lilly Ventures.
Here is the list of recent funding rounds of Forma Therapeutics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Dec 19, 2019 | $100M | Series D | 6389375 | 6344931 | |
Feb 21, 2017 | Undisclosed | Grant (prize money) | 8809064 | 7937501 | |
Apr 2014 | $225M | Series D | 5395502 | 5862778 |
Access funding benchmarks and valuations. Sign up today!View details of Forma Therapeutics's funding rounds and investors
Forma Therapeutics's founders and board of directors
The founders of Forma Therapeutics are and . is the CEO of Forma Therapeutics.
View details of Forma Therapeutics's Founder profiles and Board Members
Forma Therapeutics's employee count trend
Forma Therapeutics has 165 employees as of Dec 21. The total employee count is 66.7% more than what it was in Dec 20. Here is Forma Therapeutics's employee count trend over the years:
Uncover Forma Therapeutics's growth story! Sign up today!Forma Therapeutics's Competitors and alternates
Top competitors of Forma Therapeutics include Jazz Pharmaceuticals, Moderna and BeiGene. Here is the list of Top 10 competitors of Forma Therapeutics, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of therapeutics for cancer and neurological disorders | $265M | InterWest Partners, Investor Growth CapitalÌý&²¹³¾±è;Ìý | 85/100 |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | Flagship Pioneering, WellingtonÌý&²¹³¾±è;Ìý | 85/100 |
3rd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | T. Rowe Price, TemasekÌý&²¹³¾±è;Ìý | 84/100 |
4th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | Vivo Capital, HBM PartnersÌý&²¹³¾±è;Ìý | 82/100 |
5th | Recursion 2013, United States, Public | R&D based company focused on manufacturing of drugs for multiple therapeutic areas | $452M | HTIF, Menlo VenturesÌý&²¹³¾±è;Ìý | 81/100 |
6th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | Tekla Capital Management, Ridgeback Capital ManagementÌý&²¹³¾±è;Ìý | 78/100 |
7th |  Revolution Medicines 2014, Redwood City (United States), Public | Developer of therapies for treating cancer | $181M | Vivo Capital, DeerfieldÌý&²¹³¾±è;Ìý | 78/100 |
8th | Blueprint Medicines 2008, Cambridge (United States), Public | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | Ridgeback Capital Management, Foresite CapitalÌý&²¹³¾±è;Ìý | 76/100 |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | Aisling Capital, Frazier Healthcare PartnersÌý&²¹³¾±è;Ìý | 76/100 |
10th | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | Vulcan Capital, Foresite CapitalÌý&²¹³¾±è;Ìý | 76/100 |
218th |  2007, Watertown (United States), Acquired | Developer of therapeutic solutions for multiple health purposes | $418M | Novartis Venture Fund, WellingtonÌý&²¹³¾±è;Ìý | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Forma Therapeutics's competitors? Click to see the top ones
Forma Therapeutics's Investments and acquisitions
Forma Therapeutics has made no investments or acquisitions yet.
Reports related to Forma Therapeutics
Here is the latest report on Forma Therapeutics's sector:
View
News related to Forma Therapeutics
•
•
Business Wire•Apr 11, 2023•Cellarity, Impel Pharmaceuticals, Forma Therapeutics, Johnson & Johnson Innovation
•
•
•
•
•
•
Business Wire•Sep 30, 2022•, Forma Therapeutics
•
•
Business Wire•Sep 27, 2022•Forma Therapeutics,
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Forma Therapeutics
When was Forma Therapeutics founded?
Forma Therapeutics was founded in 2007.Where is Forma Therapeutics located?
Forma Therapeutics is located in Watertown, United States.Is Forma Therapeutics an acquired company?
Forma Therapeutics got acquired by Novo Nordisk on Sep 01, 2022.When was the latest funding round of Forma Therapeutics?
Forma Therapeutics's latest funding round was on Dec 19, 2019.What is the annual revenue of Forma Therapeutics?
Annual revenue of Forma Therapeutics is undefined as on undefined.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- St.Marys Public School - Kottayam based, 1998 founded, Unfunded company
- Adroit Progressive School - Dehradun based, Unfunded company
- NKP School - Bhubaneswar based, Unfunded company
- Mvmsagar - Sagar based, 1992 founded, Unfunded company
- Vivekanandaschool - Dehradun based, Unfunded company
- Eaemotorsports - United States based, Unfunded company
